Timothy Naumann
Psychiatric/Mental Health · Piedmont, SCNPI 1992188379
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (53.1%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. AbbVie accounts for 65.4% of it on its own, with 23 other manufacturers making up the rest. Among psychiatric/mental health clinicians in SC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 259 payments — averaging $49.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$8K
- Johnson & Johnson$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$535
- Alkermes, Inc.$430
- Supernus Pharmaceuticals, Inc.$336
- Otsuka America Pharmaceutical, Inc.$279
- plus $1K from 18 others
What the payments were for
- Speaking & faculty fees$6,75053%
- Travel & lodging$1,1549%
- Food & beverage$4,74437%
- Education$540%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 102 | $8,305 |
| Johnson & Johnson | 18 | $1,470 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 21 | $535 |
| Alkermes, Inc. | 19 | $430 |
| Supernus Pharmaceuticals, Inc. | 8 | $336 |
| Otsuka America Pharmaceutical, Inc. | 16 | $279 |
| Vanda Pharmaceuticals Inc. | 16 | $265 |
| Almatica Pharma LLC | 12 | $186 |
| Axsome Therapeutics, Inc. | 8 | $137 |
| Indivior Inc. | 5 | $114 |
| Idorsia Pharmaceuticals US Inc | 5 | $103 |
| Sunovion Pharmaceuticals Inc. | 6 | $93 |
| Lundbeck LLC | 4 | $88 |
| Braeburn Inc. | 3 | $74 |
| Corium, LLC | 4 | $70 |
| Tris Pharma Inc | 2 | $42 |
| Halozyme Inc | 2 | $34 |
| Neurocrine Biosciences, Inc. | 2 | $33 |
| E.r. Squibb & Sons, L.L.C. | 1 | $20 |
| Collegium Pharmaceutical, Inc. | 1 | $20 |
| Gilead | 1 | $19 |
| Teva Pharmaceuticals USA, Inc. | 1 | $18 |
| Biodelivery Sciences International, Inc. | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,702 in reported general payments places this provider in the 95th percentile of 354 psychiatric/mental health providers in South Carolina.
See all psychiatric/mental health providers in South Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 58 | $92,511 |
| SpravatoEsketamine Hcl | 21 | $61,739 |
| RexultiBrexpiprazole | 22 | $34,281 |
| TrintellixVortioxetine Hydrobromide | 43 | $32,152 |
| Lurasidone Hcl | 52 | $24,677 |
| AuvelityDextromethorphan Hbr/Bupropion | 11 | $15,205 |
| VyvanseLisdexamfetamine Dimesylate | 26 | $9,894 |
| Aripiprazole | 35 | $5,256 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 50 | $4,466 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 157 | $4,036 |
| Lisdexamfetamine Dimesylate | 13 | $2,960 |
| Clonazepam | 276 | $2,401 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 95 | $1,572 |
| Trazodone Hcl | 171 | $1,310 |
| Mirtazapine | 60 | $1,157 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $8,305 | $92,51158 claims |
| Johnson & JohnsonSpravato | $1,470 | $61,73921 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $14 | $42,04669 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $279 | $34,28122 claims |
| Axsome Therapeutics, Inc.Auvelity | $137 | $15,20511 claims |
| Almatica Pharma LLCSertraline Hcl | $186 | $17914 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 354 psychiatric/mental health providers in South Carolina.
Other psychiatric/mental health in Piedmont
- Steven KrozerGreenville$139K
- Luron FlemingGreenville$61K
- Cerrissa HugieCharleston$54K
- Karen FulwoodMyrtle Beach$30K
- Taylor CrewsIsle Of Palms$28K
- Lauren DyerGreenville$16K
- Melissa BrownGreenville$16K
- Mary McManusNorth Myrtle Beach$15K
- Kelsie FowlerAnderson$15K
- William HendricksGreenville$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.